FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384282493> ?p ?o ?g. }

• W4384282493 abstract "Objective The combination of nanoparticle albumin-bound paclitaxel (nab-PTX)/paclitaxel (PTX) with immune checkpoint inhibitors (ICIs) has demonstrated significant efficacy in cancer patients. However, the safety of these combination regimens remains conflicting in former researches. Therefore, in order to address this issue, we performed a systematic review and network meta-analysis (NMA) to evaluate and compare the safety profile. Methods We performed a systematic review by searching randomized controlled trials (RCTs) from PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, and Web of Science up to August 15, 2022. The primary outcomes were all‐grade (grade 1‐5) and high‐grade (grade 3‐5) immune-related adverse events (irAEs). Secondary outcomes were all‐grade (grade 1‐5) and high‐grade (grade 3‐5) irAEs of subgroups of ICIs. Results There were 22 RCTs included in the NMA, involving a total of 15 963 patients diagnosed with any type of cancer. ICIs+nab-PTX was associated with a noticeably decreased risk of grade 3-5 pneumonitis (odds ratio [OR]=0.28, 95% credible interval [CrI]: 0.09,0.90) compared to ICI monotherapy; ICIs+PTX showed a lower risk of grade 1-5 hyperthyroidism (OR=0.46, 95% CrI: 0.22-0.96) and grade 1-5 hypothyroidism (OR=0.49, 95% CrI: 0.26-0.93) than ICIs. Compared with PD-1, PD-1+PTX was associated with a statistically significantly lower risk of grade 1-5 pneumonitis (OR=0.32, 95% CrI: 0.11-0.92). PD-L1 resulted in a noticeably lower risk of grade 1-5 hypothyroidism (OR=0.34, 95% CrI: 0.12-1.00) than PD-L1+PTX. Nearly all treatment regimens containing ICIs demonstrated significantly higher risks of irAEs compared to the standard chemotherapy groups. Conclusion Nab-PTX/PTX+ICIs demonstrated an approach leading to decreased risk of irAEs compared with ICI monotherapy. This finding supports that ICIs+nab-PTX/PTX may be a safer treatment strategy. Moreover, we also found that the combination regimens containing ICIs had a higher risk of irAEs than standard chemotherapy. Additionally, ICIs+nab-PTX demonstrated a decreased risk of irAEs compared to ICIs+PTX. PD-1 inhibitors were associated with a higher risk of irAEs than PD-L1 inhibitors." @default.
• W4384282493 created "2023-07-15" @default.
• W4384282493 creator A5000790989 @default.
• W4384282493 creator A5009219696 @default.
• W4384282493 creator A5011931096 @default.
• W4384282493 creator A5027883179 @default.
• W4384282493 creator A5029088944 @default.
• W4384282493 creator A5058837031 @default.
• W4384282493 creator A5071436710 @default.
• W4384282493 date "2023-07-14" @default.
• W4384282493 modified "2023-10-18" @default.
• W4384282493 title "Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis" @default.
• W4384282493 cites W2023250799 @default.
• W4384282493 cites W2024737544 @default.
• W4384282493 cites W2043228552 @default.
• W4384282493 cites W2044202701 @default.
• W4384282493 cites W2061551675 @default.
• W4384282493 cites W2074546881 @default.
• W4384282493 cites W2075027825 @default.
• W4384282493 cites W2080878900 @default.
• W4384282493 cites W2098923148 @default.
• W4384282493 cites W2101653483 @default.
• W4384282493 cites W2130616545 @default.
• W4384282493 cites W2133294507 @default.
• W4384282493 cites W2140699272 @default.
• W4384282493 cites W2143163879 @default.
• W4384282493 cites W2145857936 @default.
• W4384282493 cites W2177405394 @default.
• W4384282493 cites W2177804157 @default.
• W4384282493 cites W2210453860 @default.
• W4384282493 cites W2222106751 @default.
• W4384282493 cites W2265285917 @default.
• W4384282493 cites W2473218705 @default.
• W4384282493 cites W2561368039 @default.
• W4384282493 cites W2572174216 @default.
• W4384282493 cites W2588681363 @default.
• W4384282493 cites W2588916311 @default.
• W4384282493 cites W2635951006 @default.
• W4384282493 cites W2766765254 @default.
• W4384282493 cites W2783137027 @default.
• W4384282493 cites W2791043965 @default.
• W4384282493 cites W2793180707 @default.
• W4384282493 cites W2797675588 @default.
• W4384282493 cites W2805354595 @default.
• W4384282493 cites W2806614796 @default.
• W4384282493 cites W2887249435 @default.
• W4384282493 cites W2895515586 @default.
• W4384282493 cites W2897422388 @default.
• W4384282493 cites W2900174742 @default.
• W4384282493 cites W2906932524 @default.
• W4384282493 cites W2925446385 @default.
• W4384282493 cites W2930693256 @default.
• W4384282493 cites W2940759533 @default.
• W4384282493 cites W2944102963 @default.
• W4384282493 cites W2946386783 @default.
• W4384282493 cites W2948776902 @default.
• W4384282493 cites W2953516553 @default.
• W4384282493 cites W2955053288 @default.
• W4384282493 cites W2972642313 @default.
• W4384282493 cites W2991836312 @default.
• W4384282493 cites W3006930853 @default.
• W4384282493 cites W3013344454 @default.
• W4384282493 cites W3016210953 @default.
• W4384282493 cites W3017322331 @default.
• W4384282493 cites W3030448313 @default.
• W4384282493 cites W3038759001 @default.
• W4384282493 cites W3038953104 @default.
• W4384282493 cites W3046869151 @default.
• W4384282493 cites W3081755429 @default.
• W4384282493 cites W3082736986 @default.
• W4384282493 cites W3084442362 @default.
• W4384282493 cites W3087466624 @default.
• W4384282493 cites W3091399767 @default.
• W4384282493 cites W3095039939 @default.
• W4384282493 cites W3112334180 @default.
• W4384282493 cites W3129022890 @default.
• W4384282493 cites W3135254573 @default.
• W4384282493 cites W3144543375 @default.
• W4384282493 cites W3144903047 @default.
• W4384282493 cites W3151427897 @default.
• W4384282493 cites W3152729586 @default.
• W4384282493 cites W3153075376 @default.
• W4384282493 cites W3153473864 @default.
• W4384282493 cites W3154805493 @default.
• W4384282493 cites W3164197656 @default.
• W4384282493 cites W3167668640 @default.
• W4384282493 cites W3172845662 @default.
• W4384282493 cites W3173705400 @default.
• W4384282493 cites W3175173749 @default.
• W4384282493 cites W3187500516 @default.
• W4384282493 cites W3188131079 @default.
• W4384282493 cites W3189379297 @default.
• W4384282493 cites W3209340745 @default.
• W4384282493 cites W4226272887 @default.
• W4384282493 cites W4236476849 @default.
• W4384282493 cites W4280533169 @default.
• W4384282493 cites W4283029993 @default.
• W4384282493 cites W4289517325 @default.
• W4384282493 cites W4378472599 @default.
• W4384282493 doi "https://doi.org/10.3389/fimmu.2023.1175809" @default.

• next